We have observed
6 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after March 20, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
NOVEL THERAPEUTIC TREATMENTS WITH ANTI-HER2 ANTIBODIES HAVING A LOW FUCOSYLATION
ANTI-CANCER TREATMENTS WITH ANTI-EGFR ANTIBODIES HAVING A LOW FUCOSYLATION
IMPROVED RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE
CONTROLLED OVARIAN HYPERSTIMULATION WITH IMPROVED RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE
EUKARYOTIC EXPRESSION VECTORS COMPRISING REGULATORY ELEMENTS OF THE GLOBIN GENE CLUSTERS
INTERNALISATION OF HUMAN HTRA1 AND CARGO PROTEINS INTO MAMMALIAN CELLS